Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 15INDUSTRY 4

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 2CNS 2

Conditions

Prostatic Neoplasms 2Disease 2Brain Neoplasms 2

Interventions

Paclitaxel 337pembrolizumab 332Carboplatin 329Cisplatin 276Gemcitabine 264Docetaxel 251Bevacizumab 239Nivolumab 230Pemetrexed 210Rituximab 183Dexamethasone 183Cyclophosphamide 169Capecitabine 169Trastuzumab 149Fluorouracil 147Ipilimumab 121atezolizumab 118Prednisone 117Erlotinib Hydrochloride 116Oxaliplatin 109Cetuximab 104Sunitinib 101Leucovorin 97Doxorubicin 97Lenalidomide 93Irinotecan 89130-nm albumin-bound paclitaxel 84durvalumab 77Bortezomib 77Azacitidine 73

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Has results × fluciclovine F-18 × Clear all
NCT04410133 2025-08-28

REVELATE

Blue Earth Diagnostics

Phase 3 Completed
151 enrolled 29 charts
CNS

Brain Neoplasms, Disease

NCT04410367 2025-07-20

PURSUE

Blue Earth Diagnostics

Phase 2 Completed
23 enrolled 10 charts
CNS

Brain Neoplasms, Disease

NCT02443571 2018-12-19

Retrospective Observational Study Investigating Fluciclovine (18F) (FACBC)

Blue Earth Diagnostics

Completed
714 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

NCT01176513 2014-02-14

GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer

GE Healthcare

Phase 2 Terminated
25 enrolled 4 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡